- The document outlines the agenda and speaker details for the 5th Biosimilars Congregation 2014 conference taking place on September 10th, 2014 in Mumbai, India.
- The conference will bring together leaders in the pharmaceutical, biotechnology, and regulatory fields to discuss challenges in biosimilar development and the evolving regulatory landscape.
- Key topics to be covered include assessing biosimilar similarity, strategic choices for biobetters and biosimilars, safety evaluation, regulatory updates, and emerging market opportunities for biosimilars in countries like India.
Dear Ladies & Gentlemen,
Hope all is well, Glad to share details with you of our upcoming conference “6th Biosimilars 2015” taking place on 10th & 11th March 2015, The Kensington Close Hotel, Wrights Lane, London, UK. Please find attached the updated agenda for the same with this email.
In case you and your colleagues would like to book as delegate there is a discounted price now :-
Introductory Offer (3 delegate places for the price of 2):- A huge saving of £ 600
Super Early Discount (Till 26th December 2014):- Conference Delegate Pass (£ 600 + VAT per delegate)
We can also offer some other sponsorship packages which include speaking opportunities/ branding etc. For some sample packages on the same please email me and I can call you to discuss the options further.
For any further assistance please feel free to contact me anytime. I look forward to a positive response from your end.
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244;
2021 Analysis and Review: Nutraceutical Gummies Market by Functionality – Digestive Health, Immunity and Strength, Cardiovascular Health, and Bone and Muscle Health for 2021 – 2031
4-Aminobutyric Acid Market Report | Global Forecast To 2028sushantkumar385
The global aminobutyric acid market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2028. The growth of this market can be attributed to the increasing demand for aminobutyric acid in food and beverage industry, pharmaceuticals and health industry, animal feeds industry. Aminobutyric acid is used as an additive in food products such as breads, cakes, biscuits and other bakery products. It is also used as a preservative in pharmaceuticals and health care products such as toothpaste, mouthwash and skin care products. Aminobutyric acid is also used in animal feeds for poultry production due to its ability to improve feed conversion ratio by reducing ammonia emissions from poultry manure.
More Details: https://industrygrowthinsights.com/report/aminobutyric-acid-market/
The healthcare industry in India is showing great progress. There has been considerable increase in spending on healthcare backed by the growing purchasing power of individuals. Moreover, with a lot of importance being given to preventive medication, the nutraceuticals market in India is set to flourish. It is one of the booming markets in India. Predominantly vitamins and minerals derived from oral pills were used for curing certain diseases and ailments. People today are becoming more prone to consume immunity enhancing food supplements and wellness related products. This is promoting the growth of the industry with players diversifying into production of various new varieties of products. Further assistance from the government and increasing demand from consumers will fuel growth in this market.
The report begins with an introduction to the Indian nutraceuticals market and its classification on the basis of the ingredients and benefits incurred from them. This is followed by the market overview section which provides the market size and growth as well as the market share of the various segments in the market, namely, functional foods, dietary supplements and functional beverages. A detailed description of each segment in the market along with the dominant products in the particular category has also been provided. Focusing on one the major sub-segments, an overview of the probiotic market in India has been included. This segment has been highlighted owing to the fact that it is one of the most promising categories under the nutraceutical market and has huge growth potential in the near future with growing interests of players. The genesis of probiotics has been highlighted showing the types dominant in India and the key therapeutic benefits derived from them. This section also contains information regarding the market size and growth of probiotics in functional foods in India as well as the key segments and the active players in this space.
This is followed by an analysis of the drivers leading to growth in the market. This includes increasing shift towards preventive therapies, increasing disposable income, increase in healthcare spending, increasing shift towards self-medication, changing demographics, growth in pharmacy and wellness related retail chains and favorable pricing environment. The key challenges to the market include lack of standardization, marketing and distribution challenges, high pricing and lack of awareness. Several trends have also been identified in the market and this has been provided in the next section. The key trends include fortified foods, ayurvedic nutraceuticals, foreign tie-ups, players educating consumers, encapsulation, and cosmeceuticals and nanoceuticals. A section on government regulations in the industry has also been included. It discusses the Food Safety and Standards Act 2006 that regulates the industry.
The competition section provides an overview of the competitive landscape in the industry and
Biopharmaceuticals are medicinal drugs which are produced through biotechnology methods such as recombinant DNA techniques, fermentation, hybridoma techniques, and purification processes. Biopharmaceutical production involves the usage of biological sources, either live organisms or their active components. They are made up of proteins and nucleic acids and target specific diseases and patients groups. Biopharmaceuticals are used in the treatment of various chronic diseases such as cardiovascular, metabolic, neurological, cancer, and other rare diseases for which there are no available treatments.
Dear Ladies & Gentlemen,
Hope all is well, Glad to share details with you of our upcoming conference “6th Biosimilars 2015” taking place on 10th & 11th March 2015, The Kensington Close Hotel, Wrights Lane, London, UK. Please find attached the updated agenda for the same with this email.
In case you and your colleagues would like to book as delegate there is a discounted price now :-
Introductory Offer (3 delegate places for the price of 2):- A huge saving of £ 600
Super Early Discount (Till 26th December 2014):- Conference Delegate Pass (£ 600 + VAT per delegate)
We can also offer some other sponsorship packages which include speaking opportunities/ branding etc. For some sample packages on the same please email me and I can call you to discuss the options further.
For any further assistance please feel free to contact me anytime. I look forward to a positive response from your end.
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244;
2021 Analysis and Review: Nutraceutical Gummies Market by Functionality – Digestive Health, Immunity and Strength, Cardiovascular Health, and Bone and Muscle Health for 2021 – 2031
4-Aminobutyric Acid Market Report | Global Forecast To 2028sushantkumar385
The global aminobutyric acid market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2028. The growth of this market can be attributed to the increasing demand for aminobutyric acid in food and beverage industry, pharmaceuticals and health industry, animal feeds industry. Aminobutyric acid is used as an additive in food products such as breads, cakes, biscuits and other bakery products. It is also used as a preservative in pharmaceuticals and health care products such as toothpaste, mouthwash and skin care products. Aminobutyric acid is also used in animal feeds for poultry production due to its ability to improve feed conversion ratio by reducing ammonia emissions from poultry manure.
More Details: https://industrygrowthinsights.com/report/aminobutyric-acid-market/
The healthcare industry in India is showing great progress. There has been considerable increase in spending on healthcare backed by the growing purchasing power of individuals. Moreover, with a lot of importance being given to preventive medication, the nutraceuticals market in India is set to flourish. It is one of the booming markets in India. Predominantly vitamins and minerals derived from oral pills were used for curing certain diseases and ailments. People today are becoming more prone to consume immunity enhancing food supplements and wellness related products. This is promoting the growth of the industry with players diversifying into production of various new varieties of products. Further assistance from the government and increasing demand from consumers will fuel growth in this market.
The report begins with an introduction to the Indian nutraceuticals market and its classification on the basis of the ingredients and benefits incurred from them. This is followed by the market overview section which provides the market size and growth as well as the market share of the various segments in the market, namely, functional foods, dietary supplements and functional beverages. A detailed description of each segment in the market along with the dominant products in the particular category has also been provided. Focusing on one the major sub-segments, an overview of the probiotic market in India has been included. This segment has been highlighted owing to the fact that it is one of the most promising categories under the nutraceutical market and has huge growth potential in the near future with growing interests of players. The genesis of probiotics has been highlighted showing the types dominant in India and the key therapeutic benefits derived from them. This section also contains information regarding the market size and growth of probiotics in functional foods in India as well as the key segments and the active players in this space.
This is followed by an analysis of the drivers leading to growth in the market. This includes increasing shift towards preventive therapies, increasing disposable income, increase in healthcare spending, increasing shift towards self-medication, changing demographics, growth in pharmacy and wellness related retail chains and favorable pricing environment. The key challenges to the market include lack of standardization, marketing and distribution challenges, high pricing and lack of awareness. Several trends have also been identified in the market and this has been provided in the next section. The key trends include fortified foods, ayurvedic nutraceuticals, foreign tie-ups, players educating consumers, encapsulation, and cosmeceuticals and nanoceuticals. A section on government regulations in the industry has also been included. It discusses the Food Safety and Standards Act 2006 that regulates the industry.
The competition section provides an overview of the competitive landscape in the industry and
Biopharmaceuticals are medicinal drugs which are produced through biotechnology methods such as recombinant DNA techniques, fermentation, hybridoma techniques, and purification processes. Biopharmaceutical production involves the usage of biological sources, either live organisms or their active components. They are made up of proteins and nucleic acids and target specific diseases and patients groups. Biopharmaceuticals are used in the treatment of various chronic diseases such as cardiovascular, metabolic, neurological, cancer, and other rare diseases for which there are no available treatments.
This presentation outlines the current state of the consumer health industry as of 2014, including market analysis, company profiles, new product launches, consumers trends, and other analyst insight.
Emergpharma`s chinese diabetes pharmaceutical market Jose Ignacio Diaz
Chinese Diabetes Pharmaceutical Market surpassed USD 3 bn in 2012 and is expected to achieve 7bn in 2007. according to Emergpharma's latest report presented yesterday. It is one of the fastest growth segment in the Global Pharmaceutical Market. Novo Nordisk, Bayer and Sanofi dominates this market with more than 50%.
Hemp Based Products Market: Outline
The use of hemp in various products and applications is rising at a great rate over the years. The medicinal benefits of hemp are tremendous and this aspect may bring substantial growth opportunities for the global hemp based products market during the forecast period of 2020-2030.
Briefing based on the key findings of my research on the Global Generic Pharmaceuticals Market 2010, covering the developed markets like the U.S, Germany, UK, France, Italy and Spain as well as the emerging markets such as India and China.
Egg White Powder Market Has Been Estimated to Account for US$ 1.3 Bn in r...VaibhavSharma864
The healthcare industry is witnessing a considerably rapid shift to a ‘preventative’ approach over treatment, which has been offering a new dimension to the perception of clinicians and patients, about the overall industry. While nutraceuticals constitute one of the key beneficiaries of this trend, it is highly likely that the opportunities will remain abound in the nutraceuticals category, for pharma and food companies, to enter the preventative healthcare landscape. By complementing each other’s strengths, dietary supplements and pharmaceuticals have blurred the application barriers of complete protein powders, such as egg white powder. This presents an exciting new opportunity to market players so as to diversify their offerings, for food processing and pharmaceutical companies.
Market research for Indian Pharmaceutical Market switching over from prescribed to OTC products. Scope of Indian Pharmaceutical OTC market, opportunities and challenges.
5th Biosimilars Congregation 2014
10th September 2014, Kohinoor Continental Hotel, Mumbai, India
“Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars”
8th Biosimilars Congregation 2016 conference which is taking place at 08th & 09th March 2016, The Kensington Close Hotel, Wrights Lane, London, UK.
For more details and registration simply email your interest and queries to Email – Deepak@virtueinsight.co.in
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
8th Biosimilars Congregation 2016 conference which is taking place at 08th & 09th March 2016, The Kensington Close Hotel, Wrights Lane, London, UK.
For more details and registration simply email your interest and queries to Email – Deepak@virtueinsight.co.in
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
This presentation outlines the current state of the consumer health industry as of 2014, including market analysis, company profiles, new product launches, consumers trends, and other analyst insight.
Emergpharma`s chinese diabetes pharmaceutical market Jose Ignacio Diaz
Chinese Diabetes Pharmaceutical Market surpassed USD 3 bn in 2012 and is expected to achieve 7bn in 2007. according to Emergpharma's latest report presented yesterday. It is one of the fastest growth segment in the Global Pharmaceutical Market. Novo Nordisk, Bayer and Sanofi dominates this market with more than 50%.
Hemp Based Products Market: Outline
The use of hemp in various products and applications is rising at a great rate over the years. The medicinal benefits of hemp are tremendous and this aspect may bring substantial growth opportunities for the global hemp based products market during the forecast period of 2020-2030.
Briefing based on the key findings of my research on the Global Generic Pharmaceuticals Market 2010, covering the developed markets like the U.S, Germany, UK, France, Italy and Spain as well as the emerging markets such as India and China.
Egg White Powder Market Has Been Estimated to Account for US$ 1.3 Bn in r...VaibhavSharma864
The healthcare industry is witnessing a considerably rapid shift to a ‘preventative’ approach over treatment, which has been offering a new dimension to the perception of clinicians and patients, about the overall industry. While nutraceuticals constitute one of the key beneficiaries of this trend, it is highly likely that the opportunities will remain abound in the nutraceuticals category, for pharma and food companies, to enter the preventative healthcare landscape. By complementing each other’s strengths, dietary supplements and pharmaceuticals have blurred the application barriers of complete protein powders, such as egg white powder. This presents an exciting new opportunity to market players so as to diversify their offerings, for food processing and pharmaceutical companies.
Market research for Indian Pharmaceutical Market switching over from prescribed to OTC products. Scope of Indian Pharmaceutical OTC market, opportunities and challenges.
5th Biosimilars Congregation 2014
10th September 2014, Kohinoor Continental Hotel, Mumbai, India
“Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars”
8th Biosimilars Congregation 2016 conference which is taking place at 08th & 09th March 2016, The Kensington Close Hotel, Wrights Lane, London, UK.
For more details and registration simply email your interest and queries to Email – Deepak@virtueinsight.co.in
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
8th Biosimilars Congregation 2016 conference which is taking place at 08th & 09th March 2016, The Kensington Close Hotel, Wrights Lane, London, UK.
For more details and registration simply email your interest and queries to Email – Deepak@virtueinsight.co.in
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
Biosimilars or follow-on-biologics are highly similar versions of reference biologics derived from living organisms such as plants and animals. The development of biosimilars and validation with reference biologics play a significant role in the commercialization of biosimilars. Economic pricing of biosimilars, ease in development and a quick approval process are some key driving factors that drive the growth of this market. Effective and timely formulated regulations facilitate the viability and balance between original and biosimilar products. Moreover, a favorable regulatory environment and the establishment of IPR protections are factors that boost the market growth.
Biosimilars or follow-on-biologics are the “copied” version of reference biologics, which are protected by intellectual rights that will expire soon. Patent expiration is the major driving factor of the biosimilars market. Most of the blockbuster patents will expire by the end of 2014, which would provide a competitive edge to local pharmaceutical manufacturers over the global players.
Greetings from Virtue Insight,
I am happy to invite you and your colleagues to be a sponsor/ delegate for our upcoming “5th Pharmacovigilance Congregation 2013” The conference will be held on 20th November 2013, Kohinoor Continental Hotel, Mumbai, India.
applied strategic founder, Dr Richard Littlewood defined success factors for the next 10-year commercial phase of biosimilars at the 8th Biosimilars Congregation, held in London.
applied strategic founder, Dr Richard Littlewood defined success factors for the next 10-year commercial phase of biosimilars at the 8th Biosimilars Congregation, held in London.
Greeting From Virtue Insight,
I am happy to invite you and your colleagues to be a sponsor/ delegate for our upcoming “9th Pharmacovigilance 2015” The conference will be held on 2nd September 2015, Kohinoor Continental Hotel, Mumbai, India.
KEY SPEAKERS:-
• V. Kalaiselvan, Principal Scientific Officer, Indian Pharmacopoeia Commission Ministry of Health and Family Welfare Govt. of India
• Arun Bhatt, President, ClinInvent Research
• Deepa Arora, Vice President - Pharmacovigilance & Global Head - Drug Safety & Risk Management, Lupin
• Bhaswat Chakraborty, Senior Vice President, Cadila
• Babita Kirodian, Head of Country Pharmacovigilance, Bristol Myers Squibb
• Nipom Deka, Regional Pharmacovigilance Manager, Asia, Africa & Middle East, Abbott
• Shashidhar Swamy, Head Pharmacovigilance, Wockhardt
• Mohammad Salim, Country Safety Lead, Pfizer
• Manish Verma, Director Medical Affairs, Sanofi
• Karthik Babu, Affiliate Pharmacovigilance Head, Sanofi
• Chirag Trivedi, Director & Head of Clinical Study Unit, Sanofi
• Priya Chatterjee, Director - Regulatory Affairs, Merck Serono
• Milind Antani, Partner In-Charge - Pharma LifeSciences, Nishith Desai Associate
• Anand Harugeri, Patient Safety and Regulatory Affairs Manager, Astrazeneca
• Deepti Sanghavi, Assistant Manager - Medical Writing, Tata Consultancy Services
• Sandeep Sewlikar, Manager – Clinical Affairs, Johnson and Johnson
• Girish Parhate, Head Regulatory Affairs, Bayer Pharmaceuticals
• Rajashri Survase Ojha, Founder and MD, Raaj GPRAC
• Vandana Jolad, Director, VIaTal Pharma
Plus Many More...
CONFERENCE BOOKING DETAILS:-
• Early Bird Discounted Price - Conference Delegate Pass (INR 6,000 + Tax (14%) per delegate) - Book and Pay before 20th July 2015 avail the early bird discounted price. You can simply email or call and book your conference delegate seats on TEL: +91 9940043915. Email – swetha@virtueinsight.co.in
• Standard Price after Early Bird Discounted Time – 1 or 2 Delegates (INR 7,000 + Tax (14%) per delegate) - You can simply email or call and book your conference delegate seats on TEL: +91 9940043915. Email – swetha@virtueinsight.co.in
• Group Discounts – 3 or 4 Delegates - (INR 6,500 + Tax (14%) per delegate)
• Group Discounts – 5 or more Delegates - (INR 5,000 + Tax (14%) per delegate)
• Conference Sponsor & Exhibition Stall - Should you wish to Sponsor, or purchase a Exhibition Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to TEL: +91 44 65515695, +91 9940043915 or swetha@virtueinsight.co.in
In case you or any of your colleagues might be interested in participating in the same, please let me know and I will be happy to call you and help you with the registration.
Thank you for your time and consideration. I look forward to hearing from you
Thanks,
Swetha
Pharma Policy 2017 - Read it in MedicinMan September 2017 IssueAnup Soans
1. Draft Pharma Policy: The Good, The Bad and The Ugly...............................................1
Interview with Sunil Attavar
2. Career Brand Plan: A Career Stepping
Stone..........................................................9
Soham Wagh
3. Succeeding as Country GM at GSK: A Whitepaper..............................................12
Sundar Ramachandran
4. Role of Digital in the Customer Journey ....................................................................21
Salil Kallianpur
5. Executive Function Disorder .................24
Vivek Hattangadi
Kseniya Leshchenko: Shared development support service model as the way to ma...Lviv Startup Club
Kseniya Leshchenko: Shared development support service model as the way to make small projects with small budgets profitable for the company (UA)
Kyiv PMDay 2024 Summer
Website – www.pmday.org
Youtube – https://www.youtube.com/startuplviv
FB – https://www.facebook.com/pmdayconference
Building Your Employer Brand with Social MediaLuanWise
Presented at The Global HR Summit, 6th June 2024
In this keynote, Luan Wise will provide invaluable insights to elevate your employer brand on social media platforms including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok. You'll learn how compelling content can authentically showcase your company culture, values, and employee experiences to support your talent acquisition and retention objectives. Additionally, you'll understand the power of employee advocacy to amplify reach and engagement – helping to position your organization as an employer of choice in today's competitive talent landscape.
"𝑩𝑬𝑮𝑼𝑵 𝑾𝑰𝑻𝑯 𝑻𝑱 𝑰𝑺 𝑯𝑨𝑳𝑭 𝑫𝑶𝑵𝑬"
𝐓𝐉 𝐂𝐨𝐦𝐬 (𝐓𝐉 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬) is a professional event agency that includes experts in the event-organizing market in Vietnam, Korea, and ASEAN countries. We provide unlimited types of events from Music concerts, Fan meetings, and Culture festivals to Corporate events, Internal company events, Golf tournaments, MICE events, and Exhibitions.
𝐓𝐉 𝐂𝐨𝐦𝐬 provides unlimited package services including such as Event organizing, Event planning, Event production, Manpower, PR marketing, Design 2D/3D, VIP protocols, Interpreter agency, etc.
Sports events - Golf competitions/billiards competitions/company sports events: dynamic and challenging
⭐ 𝐅𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐬:
➢ 2024 BAEKHYUN [Lonsdaleite] IN HO CHI MINH
➢ SUPER JUNIOR-L.S.S. THE SHOW : Th3ee Guys in HO CHI MINH
➢FreenBecky 1st Fan Meeting in Vietnam
➢CHILDREN ART EXHIBITION 2024: BEYOND BARRIERS
➢ WOW K-Music Festival 2023
➢ Winner [CROSS] Tour in HCM
➢ Super Show 9 in HCM with Super Junior
➢ HCMC - Gyeongsangbuk-do Culture and Tourism Festival
➢ Korean Vietnam Partnership - Fair with LG
➢ Korean President visits Samsung Electronics R&D Center
➢ Vietnam Food Expo with Lotte Wellfood
"𝐄𝐯𝐞𝐫𝐲 𝐞𝐯𝐞𝐧𝐭 𝐢𝐬 𝐚 𝐬𝐭𝐨𝐫𝐲, 𝐚 𝐬𝐩𝐞𝐜𝐢𝐚𝐥 𝐣𝐨𝐮𝐫𝐧𝐞𝐲. 𝐖𝐞 𝐚𝐥𝐰𝐚𝐲𝐬 𝐛𝐞𝐥𝐢𝐞𝐯𝐞 𝐭𝐡𝐚𝐭 𝐬𝐡𝐨𝐫𝐭𝐥𝐲 𝐲𝐨𝐮 𝐰𝐢𝐥𝐥 𝐛𝐞 𝐚 𝐩𝐚𝐫𝐭 𝐨𝐟 𝐨𝐮𝐫 𝐬𝐭𝐨𝐫𝐢𝐞𝐬."
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
Business Valuation Principles for EntrepreneursBen Wann
This insightful presentation is designed to equip entrepreneurs with the essential knowledge and tools needed to accurately value their businesses. Understanding business valuation is crucial for making informed decisions, whether you're seeking investment, planning to sell, or simply want to gauge your company's worth.
[Note: This is a partial preview. To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
Sustainability has become an increasingly critical topic as the world recognizes the need to protect our planet and its resources for future generations. Sustainability means meeting our current needs without compromising the ability of future generations to meet theirs. It involves long-term planning and consideration of the consequences of our actions. The goal is to create strategies that ensure the long-term viability of People, Planet, and Profit.
Leading companies such as Nike, Toyota, and Siemens are prioritizing sustainable innovation in their business models, setting an example for others to follow. In this Sustainability training presentation, you will learn key concepts, principles, and practices of sustainability applicable across industries. This training aims to create awareness and educate employees, senior executives, consultants, and other key stakeholders, including investors, policymakers, and supply chain partners, on the importance and implementation of sustainability.
LEARNING OBJECTIVES
1. Develop a comprehensive understanding of the fundamental principles and concepts that form the foundation of sustainability within corporate environments.
2. Explore the sustainability implementation model, focusing on effective measures and reporting strategies to track and communicate sustainability efforts.
3. Identify and define best practices and critical success factors essential for achieving sustainability goals within organizations.
CONTENTS
1. Introduction and Key Concepts of Sustainability
2. Principles and Practices of Sustainability
3. Measures and Reporting in Sustainability
4. Sustainability Implementation & Best Practices
To download the complete presentation, visit: https://www.oeconsulting.com.sg/training-presentations
Sustainability: Balancing the Environment, Equity & Economy
5th biosimilars congregation 2014
1. KEY SPEAKERS:-
Rohit Arora, Associate Director - Medical Affairs & Strategy Implementation,
Anita Krishnan, Senior Research Scientist,
Pravin Ghadge, Head-Medical Writing & Pharmacovigilance,
Debolina Partap, AVP & Head Legal,
Siddarth S. Chachad, Head - Clinical Development,
Ashwani Pandita, Head Quality Management & Training,
Chirag Trivedi, Director & Head of Clinical Study Unit,
Ashima Bhatia, Vice President Global Clinical Research & Development,
Suresh Maroli, Head Clinical Pharmacology,
Sofi Joseph, Head – Regulatory Operations,
Yasmin Shenoy, Director - Regulatory Affairs,
Milind Antani, Head - Pharma LifeSciences group,
Tej Krishen Bazaz, Director,
Sanofi
Lupin
Reliance Life Sciences
Wockhardt
Cipla
Glenmark
Sanofi
Wockhardt
Reliance Life Sciences
Pfizer
Sanofi Aventis
Nishith Desai Associates
Thermo Fisher Scientific
Plus Many More...
Conference Hashtag - #VI_Pharma
3. CONFERENCE INTRODUCTION:-
The biosimilar industry had a tough 2013 driven by the Indian economy having to experience one of its most turbulent times. Indian bio-pharma sector decelerated
to 5.2 per cent in 2013 from an average growth of 12 percent in the previous year. Adverse policy moves like the foreign direct investment (FDI), drug pricing,
clinical trials and compulsory licensing made the matters worse. An overactive US FDA hauled up several leading Indian pharma companies for non-compliance. All
these negative developments together turned 2013 into an 'Annus Horribilis’ for the Indian bio-pharma sector. The global biosimilars market is expected to be worth
$19.4 billion by 2014, growing at a Annual Growth Rate (CAGR) of 89.1% from 2009 to 2014.The American products Follow-on protein market (including North
America and Latin America) is expected to account for nearly 35.3% of the total income in 2014. By 2015, the sales of biosimilars is expected to hit USD 3.7bn, a
near exponential increase from USD 378 million back in 2011.
There are currently more than 80 biosimilars under development worldwide and this market could potentially become the only fastest-growing biologics sector by
2020. So, where did all this momentum come from? Why does biosimilars suddenly display an accelerated growth potential? And how have market dynamics
received and encouraged this growth? If Indian biopharmaceutical players are to compete effectively on the global scale and capture 10% of the global biosimilars
market by 2020, India’s private sector will have to invest a considerable amount of capital in building the necessary manufacturing capacity and skills base. At the
same time, the Government of India will also have to provide the necessary enabling environment. India’s biopharma sector consists primarily of monoclonal
antibodies, vaccines, recombinant proteins and diagnostics, and the guidelines for biosimilars are already in place.
Almost 50 biosimilars have already reached the Indian market, and they are sold at discounts of as much as 85%, putting them within reach of the masses. Demand
seems likely to grow considerably, as India becomes more affluent. US investment bank Goldman Sachs estimates that the number of Indians with annual incomes
of between $6,000 and $30,000 may increase by 250-300 million during the next decade alone. The global biosimilars market has even more potential for the most
efficient Indian biosimilars manufacturers, as the market will be characterised by price competition, even when there are only a less number of rival products. It is
said, the manufacturers of branded products are likely to use second-generation products with more convenient administration schedules as a means of defending
their territory. Few of these manufacturers may also try to crowd out the competition by producing their own biosimilars. So the competition is likely to be intense.
One of the most critical problem faced in India is the inaccessibility to healthcare. To address this issue, the government needs to not only relook at its public health
policy but also bring in various regulatory reforms including a smarter approval of pathway that cuts the cost of drug development to allow affordable innovations.
Regulatory reforms also need to address issues related to intellectual property and also clinical trials. Use of technology for procurement and distribution will also
enable better access to the drugs
This conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry.
Hence, this 5th Biosimilars Congregation 2014 will look at the multiple facets of biosimilars, ranging from the evolving regulatory landscape and challenges in clinical
development, to the legal and economic aspects. This Biosimilars conference will focus on multiple aspects of biosimilar product development to successfully deliver
safe, biosimilar products to the marketplace. By attending this conference you will gain a comprehensive outlook on the key issues surrounding biosimilars. This
event will provide an important platform for Biosimilars stakeholders to discuss and share best practices in expediting Biosimilars development.
It gives me great pleasure in welcoming all of you to the Virtue Insight’s 5th Biosimilars Congregation 2014. I wish and pray that all our efforts will be
beneficial to our industries folks at large.
WHY SHOULD YOU ATTEND:-
broader scope bringing the whole communications value chain together?
dedicated networking drinks time,meet the leading international vendors
Expand your knowledge
Get more from the event, with a Enjoy and make the best out
of our showcasing the products of tomorrow in the co-located
exhibition. of the latest business models and strategies in the high-level conference. Whether you are on the branded
or generic side, you cannot afford to miss this opportunity to benchmark your tactics and strategies against the industry leaders who will be the
first to traverse the pathway. Devise an immediate action plan for your biosimilar prosecution and litigation strategies in light of the barriers to
entry, research and development costs, and regulatory hurdles, which are balanced against an enormous potential for increased profit margin
KEY THEMES DISCUSSED AT THIS SUMMIT:-
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Commercialization and development strategies to gain a competitive advantage
Calculating possible revenue streams from biosimilar production
How should the pharma and generics industries approach the quickly emerging and developing biosimilar market?
What is the future of next generation Biosimilars?
The commercial challenges and opportunities to develop Biosimilars
The growing importance of biobetters over biosimilars
Gain in-depth knowledge on role of technology transfer - How does this affect market access?
How do policy makers shaping the contours of this new generic frontier, what implications they have for present biologic drug development & patent protection?
Next generation monoclonal antibody development and clinical challenges faced with biosimilar drug development
Technical case study for analytical and clinical comparability strategies
The Legal/IP for Biosimlars
How to maximise strategic partnerships to enter into the biosimlar market
New frontiers in cell line development and opportunities in biosimilars
How to reach the target audience more effectively and quickly.
Evaluating the key criteria that has to be considered to gain speedy entry into Biosimilar market
How global pharmaceutical market is turning to be more specialized & precise?
Identifying the experience on follow on biologics, generics and biosimilars has been so far
Gain up to date insight about the regulatory landscape and how it is effecting the industry
Boost your industry knowledge and relationships by networking and learning from key industry and academic leaders
WHO SHOULD ATTEND:-
CSOs, CMOs, Vice Presidents, Presidents, Heads, Directors, Team Leaders, and Senior Scientists from the following roles:
Biopharmaceuticals/ Biotherapeutics, Follow on Biologics/Follow on Proteins, Biologics/Biotechnology/ Biogenerics, Legal Affairs, Intellectual
Property, Health Economics, Pricing and Reimbursement, Clinical Immunology, Principal Scientist, Chief Scientific Officer, Process Control and
Analytical Technologies, Analytical Characterisation, Regulatory Compliance, Pharmacovigilance, Drug Safety & Risk Management, Quality Affairs/
Quality Control, New Product Development, Process Science, Portfolio Management, Research & Development, Business Development, Business
Operations, Scientific Affairs, Commercial Affairs
5th Biosimilars Congregation 2014
10th September 2014, Kohinoor Continental Hotel, Mumbai, India
4. 11:40 – Substitution And Interchangeability Of Biosimilars And
Biologics
• Regulatory aspects of interchangeability in biologics, including
biosimilars
• Issues with regard to substitution in the case of multiple
biosimilars
• Clinical aspects of substitution in biosimilars
• How will you demonstrate the higher standards of
interchangeabiity?
08:30 – Coffee and registration
09:30 – Morning Chair’s opening remarks
09:40 – Similarity in Biosimilars
10:10 – Strategic Choices For
Biobetters And Biosimilars
10:40 – Morning Coffee/Tea & Networking
• The need for similarity in analytical, biological and preclinical
aspects
• The challenges faced in achieving similarity
• Steps in assessing similarity
• Case study of a failed technology transfer for a biosimilar product
• Today’s biosimilar market and expectations for the future
• Commercial attractiveness for Antibody Drug Conjugate
• Antibody Drugs Conjugates – developing the therapeutic windows
• Leveraging the biosimilar development expertise into biobetters
Morning Keynote Address 1:
Morning Keynote Address 2:
Afternoon Chair’s person
14:00 – The Science and Business of Reference Standards
14:30 – Safety Evaluation in Biosimilars
15:00 – Afternoon Coffee/Tea & Networking
15:20 – Evaluating the potential revenue streams achievable
from biosimilar production
15:50 – Updates on current regulatory landscape
• Investing on Biosimilar: what to expect for a return on investment
(ROI)
• Profit margins in production of biosimilar
• Presentation of a biosimilar sales forecast from a manufacturing
view
• Evaluation of biosimilar in unit floor prices in a hyper-competitive
market
Anita Krishnan, Senior Research Scientist,
Pravin Ghadge, Head - Medical Writing & Pharmacovigilance,
Rohit Arora, Associate Director - Medical Affairs & Strategy
Implementation,
Lupin
Reliance Life Sciences
Sanofi
(http://www.linkedin.com/pub/anita-krishnan/11/bb9/28)
(http://www.linkedin.com/pub/dr-pravin-ghadge-
md/15/835/1a4)
(http://www.linkedin.com/in/drrohitarora)
MARKET ANALYSIS
CHALLENGES & OPPORTUNITIES
12:10 - Panel Discussion: Strategies to Improve Sponsor, Site,
and CRO
Moderator:
Panellists:
• Overview of recent trends in clinical research
• Cultural considerations for a successful partnering
• Effective biosimilars clinical study designs for india
• Identifying the role of each stakeholder
Chirag Trivedi, Director & Head of Clinical Study Unit,
Tej Krishen Bazaz, Director,
Ashima Bhatia, Vice President Global Clinical Research &
Development,
Ashwani Pandita, Head Quality Management & Training,
Sanofi
Thermo Fisher Scientific
Wockhardt
Glenmark
(http://www.linkedin.com/pub/dr-chirag-trivedi/21/b0/344)
(http://www.linkedin.com/pub/dr-tej-krishen-bazaz/17/776/612)
(http://www.linkedin.com/pub/dr-ashima-
bhatia-md/15/945/728)
(http://www.linkedin.com/pub/ashwani-pandita-rqap-
REGULATORY
5th Biosimilars Congregation 2014
10th September 2014, Kohinoor Continental Hotel, Mumbai, India
11:00 – Panel Discussion: Challenges And Opportunities For
Biosimilars In Emerging Markets
Moderator:
Panellists:
• Market size of biosimilars in the emerging market
• Selling of biosimilars in the emerging markets having government
protectionism
• Competition concentration of biosimilars in the emerging market
• Emerging markets that are highly attractive for biosimilars in india
Siddarth S. Chachad, Head - Clinical Development,
Anita Krishnan, Senior Research Scientist,
Suresh Maroli, Head Clinical Pharmacology,
Cipla
Lupin
Reliance Life
Sciences
(http://www.linkedin.com/pub/anita-krishnan/11/bb9/28)
12:50 - Networking - Take your discussions
further & build new relationships in a relaxed
& informal setting...
luncheon
5. 17:00 – Chairperson’s closing remarks and end of conference
17:10 - 18:00 Networking Drinks - Take your discussions
further & build new relationships in a relaxed
& informal setting...
16:20 – Panel Discussion: Regulatory Updates and
Development
Moderator:
Panellists:
• Clinical approvals for biosimilars
• Regulatory differences between the DCGI, FDA, EMA and local
agencies in india and other emerging markets such as china & SEA
• How to demonstrate the process consistency and its requirements
• Updates on Biosimilars guidelines in indian market
• Regulatory demand for demonstrating biosimilarity
Debolina Partap, AVP & Head Legal,
Milind Antani, Head-Pharma LifeSciences group,
Yasmin Shenoy, Director-Regulatory Affairs,
Sofi Joseph, Head–Regulatory Operations,
Wockhardt
Nishith Desai
Associates
Sanofi Aventis
Pfizer
(http://www.linkedin.com/pub/debolina-partap/1b/388/424)
(http://www.linkedin.com/pub/milind-antani/2/69a/5b5)
(http://www.linkedin.com/pub/sofi-joseph/12/307/632)
5th Biosimilars Congregation 2014
10th September 2014, Kohinoor Continental Hotel, Mumbai, India
6. FLOOR PLAN:- Book your stalls now before they run out !!!
1
2 5
3
4
CONFERENCEHALL1
CONFERENCEHALL2
CONFERENCEHALL3
1
Coffee / Tea / Networking Area
POOL
SIDE AREA
NETWORKING
LUNCHEON
4
5 6
2
3
REGISTRATION
DESK
6
5th Biosimilars Congregation 2014
FLOOR PLAN - Book your stalls now before they run out !!!
7. Queries:
Payment terms:
Substitutions/name changes or cancellations:
Indemnity:
Fee:
How we will contact you:
Should you have any questions on bookings,
Please feel free to contact us.
Email:
Web:
India Office: Tel: +91 044 64536444
Virtue Insight requires the full amount to be paid before the
conference. Virtue Insight may refuse entry to delegates who have
not paid their invoice in full.
There is a 50% liability on all bookings once made, whether by post,
fax, or email. There is a no refund policy for cancellations received
on or after one month before the start of the event. Should you decide
to cancel after this date, the full invoice must be paid. Conference
notes will then be sent to you. Unfortunately, we are unable to transfer
places between conferences and executive briefings. However, if you
cannot attend the conference, you may make a substitution/name
change at any time, as long as we are informed in writing by email,
fax or post. Name changes and substitutions must be from the same
company or organization and are not transferable between countries.
Virtue Insight reserves the right to make alterations to the
conference/executive briefing content, timing, speakers or venue
without notice. The event may be postponed or cancelled due to
unforeseen events beyond the control of Virtue Insight. If such a
situation arises, we will refund your registration fee and we will try
to reschedule the event.
The conference fee includes lunch, refreshments and conference papers
provided on the day. This fee does not include travel or hotel
accommodation.
Virtue Insight's preferred method of communication is by email and
phone. Please ensure that you complete the registration form in full
so that we can contact you.
Kohinoor Continental Hotel
Andheri Kurla Road
Andheri ( E )
Mumbai 400059 - India
Tel: 91 22 66919000 / 91 22 28209999
General information Venue:
info@virtueinsight.com
http://www.virtueinsight.com
www.virtueinsight.com
News Updates:
Please tick if you do not wish to receive email updates in
the future
Registration Form
10th September 2014, Kohinoor Continental Hotel, Mumbai, India
Early Bird Discount Rate Till 28th July 2014
Standard Rate (From 29th July 2014)
Group Bookings
Spot Registration:-
Methods of Payments:
By Bank Transfer:
1 Day conference per delegate - Fee: INR 5,000 + Tax
1 or 2 Day conference per delegate - Fee: INR 06,000 + Tax
For 3 and above delegates - per delegate - Fee: INR 05,000 + Tax
1 Day conference per delegate - Fee: INR 07,000 + Tax
Forename ............................Surname ................................
Job Title ..............................Company ................................
Official Contact Number .......................................................
Address .............................................................................
.............................................................................
Country ...............................Postcode..................................
Phone ..................................Fax ........................................
Email .................................................................................
I confirm that I have read & agree to the
terms and conditions of booking..... (Please Tick)
Signature ...........................................................................
Complete and return the above registration form via
post or email, together with your cheque payable to Virtue Insight.
Virtue Insight
830092431
IDIB000V080
Indian Bank.
118 - 119, Indira Nagar, Valasaravakkam,
Chennai 600 087,Tiruvallur district,Tamil Nadu, India
By Cheque -
Account Name -
Account Number -
Sort code -
Bank Address -
Registration Form Details:
RESERVATION PRICING: